Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I–III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial

• Published in: Nature communications Vol. 14; no. 1; pp. 8435 - 14
• Main Authors: Altorki, Nasser K., Walsh, Zachary H., Melms, Johannes C., Port, Jeffery L., Lee, Benjamin E., Nasar, Abu, Spinelli, Cathy, Caprio, Lindsay, Rogava, Meri, Ho, Patricia, Christos, Paul J., Saxena, Ashish, Elemento, Olivier, Bhinder, Bhavneet, Ager, Casey, Amin, Amit Dipak, Sanfilippo, Nicholas J., Mittal, Vivek, Borczuk, Alain C., Formenti, Silvia C., Izar, Benjamin, McGraw, Timothy E.
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 19.12.2023; Nature Publishing Group; Nature Portfolio
• Subjects: 14; 14/1; 38; 38/39; 38/91; 692/4028/546; 692/4028/67/1059/2325; 692/4028/67/1059/485; 692/699/67/1612/1350; Antibodies; Antibodies, Monoclonal - therapeutic use; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biomarkers; Carcinoma, Non-Small-Cell Lung - drug therapy; Cell survival; Clinical Trials, Phase II as Topic; Gene expression; Humanities and Social Sciences; Humans; Immunomodulation; Immunotherapy; Lung cancer; Lung Neoplasms - drug therapy; Monoclonal antibodies; multidisciplinary; Neoadjuvant Therapy; Non-small cell lung carcinoma; PD-L1 protein; Peripheral blood; Radiation; Radiation therapy; Randomized Controlled Trials as Topic; Science; Science (multidisciplinary); Small cell lung carcinoma; Small Cell Lung Carcinoma - drug therapy; Survival; Targeted cancer therapy
• ISSN: 2041-1723; 2041-1723
• DOI: 10.1038/s41467-023-44195-x

We previously reported the results of a randomized phase II trial (NCT02904954) in patients with early-stage non-small cell lung cancer (NSCLC) who were treated with either two preoperative cycles of the anti-PD-L1 antibody durvalumab alone or combined with immunomodulatory doses of stereotactic radiation (DRT). The trial met its primary endpoint of major pathological response, which was significantly higher following DRT with no new safety signals. Here, we report on the prespecified secondary endpoint of disease-free survival (DFS) regardless of treatment assignment and the prespecified exploratory analysis of DFS in each arm of the trial. DFS at 2 and 3 years across patients in both arms of the trial were 73% (95% CI: 62.1–84.5) and 65% (95% CI: 52.5–76.9) respectively. For the exploratory endpoint of DFS in each arm of the trial, three-year DFS was 63% (95% CI: 46.0–80.4) in the durvalumab monotherapy arm compared to 67% (95% CI: 49.6–83.4) in the dual therapy arm. In addition, we report post hoc exploratory analysis of progression-free survival as well as molecular correlates of response and recurrence through high-plex immunophenotyping of sequentially collected peripheral blood and gene expression profiles from resected tumors in both treatment arms. Together, our results contribute to the evolving landscape of neoadjuvant treatment regimens for NSCLC and identify easily measurable potential biomarkers of response and recurrence. The authors previously reported the primary outcomes of a randomized phase II trial comparing neoadjuvant durvalumab (anti-PD-L1) alone or in combination with stereotactic radiotherapy in patients with early-stage NSCLC. Here, the authors report the secondary outcomes of the trial and post hoc analysis.